ClinicalTrials.gg
TerminatedNCT02352753OIUpdated Dec 28, 2022Results posted

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

A Phase 3 interventional study of Denosumab in Osteogenesis Imperfecta, sponsored by Amgen. Terminated at 49 sites in 13 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-12-28.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Osteogenesis Imperfecta with a site in United States — 4 open to participants now, 11 under way, 4 of them phase 3. Osteogenesis Imperfecta · United States.

Enrollment
3rd of 28
153 · median 63
Started
2015
with 2 others
Phase 3
8 of 38
1 open now
Registered
15th of 38
by date
Lead sponsor
5 of 38
Amgen

Among the 38 studies in Osteogenesis Imperfecta with a site in United States, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 15th registered.

Osteogenesis Imperfecta

84 studies on the registry are indexed under Osteogenesis Imperfecta; 20 are open to participants now.

Browse Osteogenesis Imperfecta studies →

Open to participants now

4 of the 38 studies in Osteogenesis Imperfecta with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Osteogenesis Imperfecta studies recruiting now, 4 (29%) set no upper age limit and 8 (57%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Osteogenesis Imperfecta with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.

Read the detailed description

To evaluate the effect of denosumab in lumbar spine bone mineral density (BMD) Z-score at 12 months, as assessed by dual-energy X-ray absorptiometry (DXA), in children 2 to 17 years of age (at the time of screening) on a 3-Month Dosing Regimen with osteogenesis imperfecta (OI)

03

Conditions studied

  • Osteogenesis Imperfecta

Keywords

  • Amgen, OI, Bone
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

  • Eligibility criteria relates to initial enrollment into this study (6-Month Dosing Regimen). Subjects reconsenting to a 3-Month Dosing Regimen will not repeat eligibility assessments

Inclusion criteria

Inclusion Criteria:

  • Clinical diagnosis of OI defined as a clinical history consistent with type I-IV OI Clinical severity of OI as defined by 2 or more prevalent vertebral compression fractures; OR1 prevalent vertebral compression fracture and 1 or more nonvertebral fractures within the previous 2 years; OR 3 or more fractures within the previous 2 years.

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to comply with the requirements for frequent calcium and phosphorus monitoring for 14 days after the first dose of denosumab (only applies to the first 5 subjects age 11 to17 enrolled in the study and the first 5 subjects of any age meeting the criteria for increased bone turnover
  • Currently unhealed fracture or osteotomy as defined by orthopedic opinion
  • Osteotomy within 5 months of screening
  • Evidence of untreated oral cavities or oral infections
  • Recent or planned invasive dental procedure
  • Surgical tooth extraction which has not healed by screening
  • History of an electrophoresis pattern inconsistent with type I to IV OI
  • History of genetic testing results inconsistent with type I to IV OI
  • Abnormalities of the following per central laboratory reference ranges at screening: Serum albumin corrected calcium \< lower limit of normal (LLN) Serum vitamin D \< 20 ng/mL; re-screening for Vitamin D level \< 20 ng/mL will be allowed, after adequate supplementation
  • (AST), alanine aminotransferase (ALT) > 1.5 x (ULN)
  • Total (TBL) > 1.5 x ULN (subjects with Gilbert syndrome are eligible)
  • Serum phosphorus \< LLN
  • Serum alkaline phosphatase > 20% above the ULN or > 20% below the LLN
  • Estimated (eGFR) \< 60 mL/min/1.73 m2 (calculated bythe Schwartz equation at screening) Evidence of any of the following: Current hyperthyroidism (unless well-controlled on stable antithyroid therapy)
  • Current clinical hypothyroidism (unless well-controlled on stable thyroid replacement therapy)
  • History of hyperparathyroidism
  • Current hypoparathyroidism
  • Current, uncontrolled hypercalcemia (albumin-corrected serum Ca >10% ULN)
  • History of osteomalacia or rickets (chart review)
  • Other bone diseases that affect bone metabolism (eg, osteoporosis pseudoglioma syndrome, idiopathic juvenile osteoporosis, osteopetrosis, hypophosphatasia)
  • History of disease
  • History of rare hereditary problems of fructose intolerance
  • Positive blood screen for -1 or -2 antibody
  • Positive blood screen for surface antigen or antibody
  • Received other osteoporosis treatment or bone active treatment with the following guidelines:
  • Prior treatment with

    • denosumab
    • fluoride or strontium for bone disease (fluoride taken for routine dental care is permitted)
    • parathyroid hormone (PTH) or PTH derivatives within 12 months prior to screening
    • zoledronic acid within 6 months prior to screening
    • oral bisphosphonates or intravenous bisphosphonates other than zoledronic acid if the first dose of denosumab would be before their next scheduled bisphosphonate dose would have been given
  • Administration of systemic (≥ 5.0 mg prednisone equivalents/day for more than 10 days) within 3 months of screening.
  • Topical and inhaled glucocorticoids will be allowed
  • Administration of any of the following treatment within 3 months of screening:

    • Growth hormone (subjects on stable dose of growth hormone for at least 3 months prior to screening will be allowed)
  • Currently receiving treatment in another drug study, or less than 30 days since ending treatment on another investigational drugstudy(s), or current or planned participation in a clinical trial that would preclude compliance with study requirements Other inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Denosumab

    Participants received denosumab 1 mg/kg (up to a maximum of 60 mg) subcutaneously every 6 months (Q6M) for up to 36 months. Early efficacy and PK data from Q6M dosing supported adjustment of the dosing regimen from Q6M to every 3 months (Q3M). Participants enrolled and still receiving denosumab were transitioned from Q6M to Q3M dosing schedule. Participants could transition to Q3M dosing schedule up to and including the date they attended for their month 36 visit under the Q6M dosing regimen. Those participants received denosumab during the Q3M dosing regimen for 12 months. Participants who transition to Q3M at month 18 of the Q6M dosing regimen received denosumab Q3M for up to 18 months.

    Drug: Denosumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 Months

    Lumbar spine BMD was measured by dual-energy X-ray absorptiometry (DXA) adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.

    Time frame: Baseline and 12 months

Secondary outcomes

  1. Change From Baseline in Lumbar Spine BMD Z-score at 6 Months

    Lumbar spine BMD was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.

    Time frame: Baseline and 6 months

  2. Change From Baseline in Proximal Femur BMD Z-score at 6 and 12 Months

    Proximal femur (total hip and femoral neck) BMD Z-score was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.

    Time frame: Baseline, 6 and 12 months

  3. Percentage of Participants With at Least 1 X-ray Confirmed Long Bone or New and Worsening Vertebral Fracture

    Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months

  4. Percentage of Participants With at Least 1 X-ray Confirmed New and Worsening Vertebral Fracture

    Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months

  5. Percentage of Participants With at Least 1 X-ray Confirmed New Vertebral Fracture

    Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months

  6. Percentage of Participants Wth at Least 1 X-ray Confirmed Improving Vertebral Fracture

    Time frame: Q3M Dosing Regimen: Baseline up to 12 months

  7. Percentage of Participants With at Least 1 Vertebral and Nonvertebral Fracture

    Time frame: Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months

  8. Change From Baseline in Child Health Questionnaire-Parent Form Physical Summary Score (CHQ-PF-50) at 12 Months

    The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A negative change from Baseline indicates decreased well-being.

    Time frame: Baseline and 12 months

  9. Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12 Months

    The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A positive change from Baseline indicates improved well-being.

    Time frame: Baseline and 12 months

  10. Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12 Months

    The disability domain (questions 1-54) of the CHAQ was used to measure the participant's assessment of physical functioning or the parent's assessment of the child's physical functioning. The disability index comprised of 8 categories (dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and activities). Scoring ranged from 1 to 5; 1 was "without any difficulty," 2 was "with some difficulty," 3 was "with much difficulty," and 4 was "unable to do." An answer of "not applicable" was scored as a 5, but was not counted. If a child required assistance from another person or used an aid or other device for any of the 8 categories, the minimum score for that category was recorded as a 3. The CHAQ questions were scored and converted to a total index score ranging from 0 to 3. Negative change from Baseline indicates an improvement.

    Time frame: Baseline and 12 months

  11. Change From Baseline in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12 Months

    Participants were asked to report their level of pain by choosing a face that best described their own pain (the corresponding number: 0, 2, 4, 6, 8, 10) were then recorded. The WBFPRS ranged from 0, "no hurt," to 10, "hurts worst". A negative change from baseline indicates an improvement.

    Time frame: Baseline and 12 months

  12. Serum Concentration of Denosumab

    Time frame: Days 1 (predose), 10, 30, and 60, & weeks 12, 24, 36, 48, 60, 72 (end of study visit), early termination visit, & follow-up visit 12 weeks after last dose (average duration of treatment: 231 days)

  13. Serum Bone Turnover Marker (BTM) - Serum Type I Collagen C Telopeptide

    Time frame: Baseline and Days 10 and 30, and Months 3, 6, 9, 12, 15 and 18

  14. BTM - Bone-specific Alkaline Phosphatase (BSAP)

    Time frame: Baseline and Days 10 and 30, and Months 3, 6, 9, 12, and 15

  15. Change From Baseline in Growth Velocity at 12 Months

    Change from baseline in growth velocity was determined by calculating age-adjusted Z-scores for height, weight and body mass index (BMI). Height-for-age Z-score was defined as the difference between the participant's height and the median height for the population with the same age and gender, divided by the population standard deviation. The definitions of growth velocity based on weight and BMI were analogously calculated. To programmatically calculate the Z-scores, the National Center for Health Statistics percentiles growth charts, based on the 2000 Center for Disease Control and Prevention (CDC) (http://www.cdc.gov/growthcharts/c c_charts.htm), and the CDC Anthropometric Software Package 3.0 Z-scores were used. During normal growth, the change in z-score for each of the three should equal 0. A positive change in any of the three indicates growth acceleration, whereas a negative change indicates deceleration.

    Time frame: Baseline and 12 months

07

Results

Posted Dec 28, 2022

Participant flow

The study was conducted at 32 centers in North America, Europe, and Australia from June 2015 to March 2022.

6-Month Dosing Period
Participant flow — 6-Month Dosing Period
MilestoneDenosumab
Started153
Received investigational product153
Completed55
Not completed98
Withdrew: Decision by sponsor2
Withdrew: Withdrawal by subject34
Withdrew: Lost to follow-up2
Withdrew: Transitioning to q3m60
3-Month Dosing Period
Participant flow — 3-Month Dosing Period
MilestoneDenosumab
Started60
Received investigational product60
Completed40
Not completed20
Withdrew: Decision by sponsor14
Withdrew: Withdrawal by subject6

Outcome measures

PrimaryChange From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 Months

Lumbar spine BMD was measured by dual-energy X-ray absorptiometry (DXA) adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.

Time frame:
Baseline and 12 months
Reported as:
Least squares mean · Z-score
Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 Months
Z-scoreDenosumab 3-Month Dosing Regimen
Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score at 12 Months1.009 ± 0.119
SecondaryChange From Baseline in Lumbar Spine BMD Z-score at 6 Months

Lumbar spine BMD was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.

Time frame:
Baseline and 6 months
Reported as:
Least squares mean · Z-score
Change From Baseline in Lumbar Spine BMD Z-score at 6 Months
Z-scoreDenosumab 3-Month Dosing Regimen
Change From Baseline in Lumbar Spine BMD Z-score at 6 Months0.925 ± 0.078
SecondaryChange From Baseline in Proximal Femur BMD Z-score at 6 and 12 Months

Proximal femur (total hip and femoral neck) BMD Z-score was measured by DXA adjusted for age, sex, and race/ethnicity. The results were then converted to Z-scores. The Z-score indicated the number of standard deviations away from the reference population and a score of 0 is equal to the mean. Positive changes from Baseline indicated an improvement in lumbar spine BMD.

Time frame:
Baseline, 6 and 12 months
Reported as:
Least squares mean · Z score
Change From Baseline in Proximal Femur BMD Z-score at 6 and 12 Months
Z scoreDenosumab 3-Month Dosing Regimen
Total hip BMD Z-score - 6 Months0.799 ± 0.082
Total hip BMD Z-score - 12 Months0.793 ± 0.154
Femoral neck BMD Z-score - 6 Months0.769 ± 0.067
Femoral neck BMD Z-score - 12 Months0.689 ± 0.131
SecondaryPercentage of Participants With at Least 1 X-ray Confirmed Long Bone or New and Worsening Vertebral Fracture
Time frame:
Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 X-ray Confirmed Long Bone or New and Worsening Vertebral Fracture
Percentage of participantsDenosumab 6-Month Dosing RegimenDenosumab 3-Month Dosing Regimen
Percentage of Participants With at Least 1 X-ray Confirmed Long Bone or New and Worsening Vertebral Fracture28.326.7
SecondaryPercentage of Participants With at Least 1 X-ray Confirmed New and Worsening Vertebral Fracture
Time frame:
Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 X-ray Confirmed New and Worsening Vertebral Fracture
Percentage of participantsDenosumab 6-Month Dosing RegimenDenosumab 3-Month Dosing Regimen
Percentage of Participants With at Least 1 X-ray Confirmed New and Worsening Vertebral Fracture12.88.5
SecondaryPercentage of Participants With at Least 1 X-ray Confirmed New Vertebral Fracture
Time frame:
Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 X-ray Confirmed New Vertebral Fracture
Percentage of participantsDenosumab 6-Month Dosing RegimenDenosumab 3-Month Dosing Regimen
Percentage of Participants With at Least 1 X-ray Confirmed New Vertebral Fracture10.66.4
SecondaryPercentage of Participants Wth at Least 1 X-ray Confirmed Improving Vertebral Fracture
Time frame:
Q3M Dosing Regimen: Baseline up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants Wth at Least 1 X-ray Confirmed Improving Vertebral Fracture
Percentage of participantsDenosumab 3-Month Dosing Regimen
Percentage of Participants Wth at Least 1 X-ray Confirmed Improving Vertebral Fracture27.7
SecondaryPercentage of Participants With at Least 1 Vertebral and Nonvertebral Fracture
Time frame:
Q6M Dosing Regimen: Last 12 months of treatment (median treatment duration was 730.0 days); Q3M Dosing Regimen: Day 1 up to 12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Vertebral and Nonvertebral Fracture
Percentage of participantsDenosumab 6-Month Dosing RegimenDenosumab 3-Month Dosing Regimen
Percentage of Participants With at Least 1 Vertebral and Nonvertebral Fracture28.630.4
SecondaryChange From Baseline in Child Health Questionnaire-Parent Form Physical Summary Score (CHQ-PF-50) at 12 Months

The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A negative change from Baseline indicates decreased well-being.

Time frame:
Baseline and 12 months
Reported as:
Mean · Score on a scale
Change From Baseline in Child Health Questionnaire-Parent Form Physical Summary Score (CHQ-PF-50) at 12 Months
Score on a scaleDenosumab 3-Month Dosing Regimen
Change From Baseline in Child Health Questionnaire-Parent Form Physical Summary Score (CHQ-PF-50) at 12 Months-0.98 ± 15.41
SecondaryChange From Baseline in CHQ-PF-50 Psychological Summary Score at 12 Months

The CHQ-PF-50 was a 50-item questionnaire completed by the parents or guardians of children between 5 and 18 years of age. The 50 questions measure 14 domains which were summarized as the physical and psychological summary scores. Each summary score was transformed and could range from 0 to 100, with higher score indicating better physical and psychosocial health. A positive change from Baseline indicates improved well-being.

Time frame:
Baseline and 12 months
Reported as:
Mean · Score on a scale
Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12 Months
Score on a scaleDenosumab 3-Month Dosing Regimen
Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12 Months0.85 ± 8.57
SecondaryChange From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12 Months

The disability domain (questions 1-54) of the CHAQ was used to measure the participant's assessment of physical functioning or the parent's assessment of the child's physical functioning. The disability index comprised of 8 categories (dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and activities). Scoring ranged from 1 to 5; 1 was "without any difficulty," 2 was "with some difficulty," 3 was "with much difficulty," and 4 was "unable to do." An answer of "not applicable" was scored as a 5, but was not counted. If a child required assistance from another person or used an aid or other device for any of the 8 categories, the minimum score for that category was recorded as a 3. The CHAQ questions were scored and converted to a total index score ranging from 0 to 3. Negative change from Baseline indicates an improvement.

Time frame:
Baseline and 12 months
Reported as:
Mean · Score on a scale
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12 Months
Score on a scaleDenosumab 3-Month Dosing Regimen
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12 Months-0.06 ± 0.46
SecondaryChange From Baseline in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12 Months

Participants were asked to report their level of pain by choosing a face that best described their own pain (the corresponding number: 0, 2, 4, 6, 8, 10) were then recorded. The WBFPRS ranged from 0, "no hurt," to 10, "hurts worst". A negative change from baseline indicates an improvement.

Time frame:
Baseline and 12 months
Reported as:
Mean · Score on a scale
Change From Baseline in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12 Months
Score on a scaleDenosumab 3-Month Dosing Regimen
Change From Baseline in Wong-Baker Faces Pain Rating Scale (WBFPRS) at 12 Months0.0 ± 1.7
SecondarySerum Concentration of Denosumab
Time frame:
Days 1 (predose), 10, 30, and 60, & weeks 12, 24, 36, 48, 60, 72 (end of study visit), early termination visit, & follow-up visit 12 weeks after last dose (average duration of treatment: 231 days)
Reported as:
Mean · ng/mL
Serum Concentration of Denosumab
ng/mLDenosumab 3-Month Dosing Regimen
Day 18.1 ± 62.0
Day 106685.4 ± 1761.8
Day 303840.5 ± 1329.9
Day 601291.4 ± 971.2
Week 12 Day 1406.2 ± 627.0
Week 24 Day 1589.8 ± 804.3
Week 36835.1 ± 983.5
Week 48647.3 ± 875.1
Week 601266.7 ± 861.1
Week 72970.0 ± 1371.8
Early Termination Visit4.2 ± 11.8
Week 12 Follow-up Visit72.6 ± 103.9
SecondarySerum Bone Turnover Marker (BTM) - Serum Type I Collagen C Telopeptide
Time frame:
Baseline and Days 10 and 30, and Months 3, 6, 9, 12, 15 and 18
Reported as:
Mean · ng/L
Serum Bone Turnover Marker (BTM) - Serum Type I Collagen C Telopeptide
ng/LDenosumab 3-Month Dosing Regimen
Baseline1136.5 ± 569.7
Day 10174.4 ± 64.7
Day 30176.5 ± 87.9
Month 3498.4 ± 332.0
Month 6537.1 ± 427.1
Month 9539.0 ± 425.0
Month 12681.2 ± 563.1
Month 151050.8 ± 758.8
Month 181290.0 ± NA
SecondaryBTM - Bone-specific Alkaline Phosphatase (BSAP)
Time frame:
Baseline and Days 10 and 30, and Months 3, 6, 9, 12, and 15
Reported as:
Mean · μg/L
BTM - Bone-specific Alkaline Phosphatase (BSAP)
μg/LDenosumab 3-Month Dosing Regimen
Baseline69.22 ± 34.26
Day 1070.88 ± 32.77
Day 3056.28 ± 28.32
Month 3498.4 ± 332.0
Month 640.30 ± 22.58
Month 951.17 ± 106.27
Month 1240.02 ± 27.64
Month 1549.49 ± 31.20
SecondaryChange From Baseline in Growth Velocity at 12 Months

Change from baseline in growth velocity was determined by calculating age-adjusted Z-scores for height, weight and body mass index (BMI). Height-for-age Z-score was defined as the difference between the participant's height and the median height for the population with the same age and gender, divided by the population standard deviation. The definitions of growth velocity based on weight and BMI were analogously calculated. To programmatically calculate the Z-scores, the National Center for Health Statistics percentiles growth charts, based on the 2000 Center for Disease Control and Prevention (CDC) (http://www.cdc.gov/growthcharts/c c_charts.htm), and the CDC Anthropometric Software Package 3.0 Z-scores were used. During normal growth, the change in z-score for each of the three should equal 0. A positive change in any of the three indicates growth acceleration, whereas a negative change indicates deceleration.

Time frame:
Baseline and 12 months
Reported as:
Mean · Z-score
Change From Baseline in Growth Velocity at 12 Months
Z-scoreDenosumab 3-Month Dosing Regimen
Height -for-age Z-score-0.01 ± 0.43
Weight-for-age Z-score0.01 ± 0.53
BMI-for-age Z-score-0.07 ± 0.52

Adverse events

Collected over 6QM dosing regimen: Day 1 up to 36 months 3QM dosing regimen: Day 1 up to 24 weeks after last dose (median duration of treatment was 253 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab 6-Month Dosing Regimen0/153 (0%)52/153 (34%)141/153 (92.2%)
Denosumab 3-Month Dosing Regimen0/60 (0%)12/60 (20%)38/60 (63.3%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventDenosumab 6-Month Dosing RegimenDenosumab 3-Month Dosing Regimen
HypercalcaemiaMetabolism and nutrition disorders0/1538/60
Femur fractureInjury, poisoning and procedural complications15/1532/60
Tibia fractureInjury, poisoning and procedural complications10/1532/60
Humerus fractureInjury, poisoning and procedural complications8/1530/60
Fibula fractureInjury, poisoning and procedural complications7/1531/60
Lumbar vertebral fractureInjury, poisoning and procedural complications5/1530/60
Radius fractureInjury, poisoning and procedural complications5/1531/60
Ulna fractureInjury, poisoning and procedural complications4/1531/60
Device dislocationProduct Issues4/1530/60
General physical health deteriorationGeneral disorders0/1531/60
Most frequent other events
Showing 10 of 35
Most frequent other events
EventDenosumab 6-Month Dosing RegimenDenosumab 3-Month Dosing Regimen
ArthralgiaMusculoskeletal and connective tissue disorders70/15315/60
Pain in extremityMusculoskeletal and connective tissue disorders57/15311/60
Back painMusculoskeletal and connective tissue disorders50/1535/60
HypercalciuriaRenal and urinary disorders49/1535/60
HypercalcaemiaMetabolism and nutrition disorders28/15315/60
FallInjury, poisoning and procedural complications25/1536/60
NasopharyngitisInfections and infestations23/1537/60
Bone painMusculoskeletal and connective tissue disorders21/1531/60
HeadacheNervous system disorders21/1534/60
PyrexiaGeneral disorders18/1531/60

Baseline characteristics

The full analysis set (FAS) included all participants who enrolled into the study.

Age, Continuous
Age, Continuous(Years)Denosumab
Mean9.3 ± 3.9
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab
Female73
Male80
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Denosumab
Hispanic or Latino15
Not Hispanic or Latino138
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Denosumab
Asian4
Black or African American2
White135
Other8
Multiple4
08

Study locations

49 sites
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Wilmington, Delaware 19803, United States
  • Research Site
    Decatur, Georgia 30033, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Baltimore, Maryland 21205, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Omaha, Nebraska 68114, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Westmead, New South Wales 2145, Australia
  • Research Site
    Subiaco, Western Australia 6008, Australia
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Sofia, 1784, Bulgaria
  • Research Site
    Varna, 9010, Bulgaria
  • Research Site
    Ottawa, Ontario K1H 8L1, Canada
  • Research Site
    Toronto, Ontario M5G 1X8, Canada
  • Research Site
    Montreal, Quebec H4A 0A9, Canada
  • Research Site
    Hradec Kralove, 500 05, Czechia
  • Research Site
    Pardubice, 532 03, Czechia
  • Research Site
    Plzen, 305 99, Czechia
  • Research Site
    Praha 4, 140 59, Czechia
  • Research Site
    Zlin, 762 75, Czechia
  • Research Site
    Bordeaux Cedex, 33076, France
  • Research Site
    Paris Cedex 15, 75743, France
  • Research Site
    Paris, 75012, France
  • Research Site
    Saint Priest en Jarez, 42270, France
  • Research Site
    Toulouse Cedex 9, 31059, France
  • Research Site
    Köln, 50931, Germany
  • Research Site
    Budapest, 1094, Hungary
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Verona, 37126, Italy
  • Research Site
    Bialystok, 15-274, Poland
  • Research Site
    Lodz, 91-738, Poland
  • Research Site
    Rzeszow, 35-301, Poland
  • Research Site
    Warszawa, 04-730, Poland
  • Research Site
    Esplugues de Llobregat, Cataluña 08950, Spain
  • Research Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Research Site
    Getafe, Madrid 28905, Spain
  • Research Site
    Birmingham, B4 6NH, United Kingdom
  • Research Site
    Bristol, BS2 8AE, United Kingdom
  • Research Site
    Glasgow, G51 4TF, United Kingdom
  • Research Site
    Sheffield, S10 2TH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Mar 2022, 81 months.

Results were first posted in Dec 2022, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2015
First posted
Feb 2, 2015
StartActual
Jun 24, 2015
Primary completionActual
Mar 26, 2022
CompletionActual
Mar 26, 2022
Results first posted
Dec 28, 2022
Last update
Dec 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02352753
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 2, 2015
Start date
Jun 24, 2015
Primary completion
Mar 26, 2022
Completion
Mar 26, 2022
Results posted
Dec 28, 2022
Last update
Dec 28, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion